Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
Moderna Receives Health Canada Approval for RSV Vaccine for …
Nov 8, 2024 · mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory ...
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · CNN — The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under...
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to ... - MedCity News
May 31, 2024 · Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their...
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA…
Aug 23, 2024 · mRESVIA ® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells.
ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine ...
Sep 5, 2024 · Learn more about the ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease.
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, or RSV, infection.
FDA approves Moderna’s RSV vaccine, its second licensed …
May 31, 2024 · The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed...
Moderna Receives Health Canada Approval for RSV Vaccine for
6 days ago · mRESVIA is the only RSV vaccine available in a pre-filled syringe. This format offers a convenient, ready-to-use formulation that simplifies the process of administering the vaccine, saving healthcare professionals time and reducing the risk of administrative errors. Supply of mRESVIA is anticipated in Canada in early 2025.
FDA approves mRNA-based RSV vaccine - Nature
Jun 7, 2024 · The FDA has approved Moderna’s mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) to protect adults aged 60 years and older from lower respiratory tract disease....